ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2019
Microfluidic Multitissue Platform for Advanced Embryotoxicity Testing In Vitro.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- A quantitative meta-analysis comparing cell models in perfused organ on a chip with static cell cultures.Scientific reports · 2023Pooled it
- A perfused, parallelized blood brain barrier-tumor platform for compound permeation and efficacy investigations.Microsystems & nanoengineering · 2026Article
- Seamless integration of CMOS microsensors into open microfluidic systems.Lab on a chip · 2025Article
- The Synergy between Deep Learning and Organs-on-Chips for High-Throughput Drug Screening: A Review.Biosensors · 2023Review
- Recent advances in liver-on-chips: Design, fabrication, and applications.Smart medicine · 2023Review
- Microphysiological Drug-Testing Platform for Identifying Responses to Prodrug Treatment in Primary Leukemia.Advanced healthcare materials · 2023Article
- Liver-on-a-chip: Considerations, advances, and beyond.Biomicrofluidics · 2022Review
- Organs-on-Chips Platforms Are Everywhere: A Zoom on Biomedical Investigation.Bioengineering (Basel, Switzerland) · 2022Review
- A High-Throughput and Uniform Amplification Method for Cell Spheroids.Micromachines · 2022Article
- Circuit-Based Design of Microfluidic Drop Networks.Micromachines · 2022Review
- Review
- An Overview of Organs-on-Chips Based on Deep Learning.Research (Washington, D.C.) · 2022Review
- A review for cell-based screening methods in drug discovery.Biophysics reports · 2021Article
- A dynamic microscale mid-throughput fibrosis model to investigate the effects of different ratios of cardiomyocytes and fibroblasts.Lab on a chip · 2021Article
- Organs-on-chips: into the next decade.Nature reviews. Drug discovery · 2021Review
- A Micropatterned Human-Specific Neuroepithelial Tissue for Modeling Gene and Drug-Induced Neurodevelopmental Defects.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Tissue Chips and Microphysiological Systems for Disease Modeling and Drug Testing.Micromachines · 2021Review
- Recent insights on indirect mechanisms in developmental toxicity of nanomaterials.Particle and fibre toxicology · 2020Review
- In Vitro Platform for Studying Human Insulin Release Dynamics of Single Pancreatic Islet Microtissues at High Resolution.Advanced biosystems · 2020Article
- In vitro models of neuromuscular junctions and their potential for novel drug discovery and development.Expert opinion on drug discovery · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The integration of metabolic competence in developmental toxicity assays in vitro is of fundamental importance to better predict adverse drug effects. Here, a microfluidic hanging-drop platform is presented that seamlessly integrates liver metabolism into the embryonic stem cell test (EST). Primary human liver microtissues (hLiMTs) and embryoid bodies (EBs) are combined in the same fluidic network, so that hLiMT-generated metabolites are directly transported to the EBs. Gravity-driven flow through the network enables continuous intertissue communication, constant medium turnover, and, most importantly, immediate exchange of metabolites. As a proof of concept, the prodrug cyclophosphamide is investigated and a fourfold lower ID50 concentration (50% inhibition of EB differentiation) is found after biotransformation, which demonstrates the potentially adverse effects of metabolites on embryotoxicity. The metaEST platform provides a promising tool to increase the predictive power of the current EST assay by more comprehensively including and better reflecting physiological processes in in vitro tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.